Compounds > ribavirin
Page last updated: 2024-08-16

ribavirin and alisporivir

ribavirin has been researched along with alisporivir in 9 studies

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (11.11)29.6817
2010's8 (88.89)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Coelmont, L; Dumont, JM; Kaptein, S; Neyts, J; Paeshuyse, J; Vliegen, I; Vuagniaux, G1
Hokari, A1
Espinales, JC; Lawitz, EJ; Membreno, FE1
Guedj, J; Kern, S; Levi, M; Li, B; Naoumov, NV; Perelson, AS; Yu, J1
Ampuero, J; Reddy, KR; Romero-Gómez, M1
Alberti, A; Brass, C; Buti, M; Calistru, P; Chuang, WL; Davis, GL; Flisiak, R; Goeser, T; Horban, A; Kao, JH; Mazzella, G; Orsenigo, R; Pol, S; Rasenack, J; Streinu-Cercel, A; Tabak, F1
Avila, C; Chuang, WL; Flisiak, R; Foster, GR; Hézode, C; Li, B; Naoumov, NV; Pawlotsky, JM; Peng, CY; Piratvisuth, T; Rasenack, J; Sarin, SK; Shah, S; Wedemeyer, H; Wong, KA; Zhang, W1
Abdurakhmanov, D; Bao, W; Brass, C; Buggisch, P; Calistru, P; Flisiak, R; Gould, M; Griffel, LH; Heo, J; Hsu, SJ; Makara, M; Mazur, W; Mazzella, G; Merz, M; Mutimer, D; Naoumov, NV; Nault, B; Samuel, D; Stanciu, C; Thongsawat, S; Van Kính, N; Vierling, JM; Zeuzem, S1
Bo, Q; Brass, C; Griffel, L; Orsenigo, R; Wang, J1

Reviews

3 review(s) available for ribavirin and alisporivir

ArticleYear
[Improved virologic response in chronic hepatitis C treated with peginterferon, ribavirin and add-on drug].
    Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69 Suppl 4

    Topics: Antiviral Agents; Cyclosporine; Diterpenes; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fatty Alcohols; Female; Fluvastatin; Hepatitis C, Chronic; Humans; Indoles; Interferon-alpha; Male; Metformin; Nitro Compounds; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Silybin; Silymarin; Thiazoles

2011
Cyclophilin inhibitors for hepatitis C therapy.
    Clinics in liver disease, 2013, Volume: 17, Issue:1

    Topics: Antiviral Agents; Cyclophilins; Cyclosporine; Cyclosporins; Drug Therapy, Combination; Enzyme Inhibitors; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Nonstructural Proteins

2013
Review article: HCV genotype 3 – the new treatment challenge.
    Alimentary pharmacology & therapeutics, 2014, Volume: 39, Issue:7

    Topics: Animals; Antiviral Agents; Cyclophilins; Cyclosporine; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Ribavirin; Viral Nonstructural Proteins

2014

Trials

4 trial(s) available for ribavirin and alisporivir

ArticleYear
Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patients.
    Hepatology (Baltimore, Md.), 2014, Volume: 59, Issue:5

    Topics: Antiviral Agents; Cyclosporine; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2014
Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial.
    Journal of viral hepatitis, 2015, Volume: 22, Issue:7

    Topics: Adult; Aged; Antiviral Agents; Cyclosporine; Double-Blind Method; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Placebos; Ribavirin; Salvage Therapy; Treatment Outcome; Viral Load; Young Adult

2015
Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection.
    Hepatology (Baltimore, Md.), 2015, Volume: 62, Issue:4

    Topics: Adult; Antiviral Agents; Cyclosporine; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2015
Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II).
    Alimentary pharmacology & therapeutics, 2015, Volume: 42, Issue:7

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Cyclosporine; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; United States; Young Adult

2015

Other Studies

2 other study(ies) available for ribavirin and alisporivir

ArticleYear
Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:3

    Topics: Antiviral Agents; Clinical Trials as Topic; Cyclophilins; Cyclosporine; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Hepacivirus; Hepatitis C; Humans; Replicon; Ribavirin; Viral Nonstructural Proteins

2009
Glucose abnormalities in Asian patients with chronic hepatitis C.
    Drug design, development and therapy, 2015, Volume: 9

    Topics: Adult; Age Factors; Antiviral Agents; Asian People; Blood Glucose; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclosporine; Diabetes Mellitus, Type 2; Female; Hepatitis C, Chronic; Humans; Interferons; Logistic Models; Male; Middle Aged; Randomized Controlled Trials as Topic; Retrospective Studies; Ribavirin; Risk Factors; Sex Factors; Treatment Outcome

2015